FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134973524> ?p ?o ?g. }

• W3134973524 endingPage "1248" @default.
• W3134973524 startingPage "1233" @default.
• W3134973524 abstract "Treatment using add-on antidepressants with antipsychotic drugs in negative symptoms of schizophrenia has been reviewed recently in comprehensive meta-analyses. Tranylcypromine (TCP), an irreversible monoamine oxidase (MAO)-A/B inhibitor applied in treatment resistant depression, was not included because of strict requirements for quality of study design. To get a clear picture of available evidence for this resource in the treatment of schizophrenia, we conducted a review and meta-analysis of add-on TCP in the treatment of predominant negative symptoms of schizophrenia (negative schizophrenia).Seven controlled studies of add-on TCP in schizophrenia with predominant negative symptoms were found in a search of multiple databases. A subset of four studies of the prospective and parallel comparison of add-on TCP with antipsychotic drugs vs. antipsychotic drug monotherapy and meeting minimum quality criteria formed the primary meta-analysis. The effect size was calculated as the natural logarithm of the odds ratio (logOR) of responders and non-responders.In the primary meta-analysis, a pooled logOR = 1.092 with 95%CI 0.410-1.774 (I2 = 43.4%, moderate heterogeneity) was calculated according to a fixed-effect model. Heterogeneity was reduced for three double-blind studies of add-on TCP with trifluoperazine (TFP) vs. TFP-monotherapy and resulted a pooled logOR = 0.916 with 95%CI 0.216-1.616 (I2 negative, no heterogeneity). A significant logOR = 1.558 with 95%CI 0.340-2.776 was found for TCP/TFP compared to placebo in one study. In a meta-analysis of extrapyramidal adverse effects, studies were very heterogeneous and revealed no significant differences between treatments. The risk of exacerbation of positive symptoms with add-on TCP was found to be very low for a duration of treatment of 12-16 weeks. No cases of hypertensive crisis were reported. The main methodical limitations were insufficient description of randomization or matching of patients without randomization. The main clinical limitation is a gap of data for add-on TCP with second-generation antipsychotics.New studies are needed for add-on TCP with antipsychotic drugs in schizophrenia with predominant negative symptoms. Trials of this treatment may be possible in rare and selected cases. The therapeutic effect of add-on TCP may be explained by a strong dopaminergic activity." @default.
• W3134973524 created "2021-03-15" @default.
• W3134973524 creator A5011519841 @default.
• W3134973524 creator A5045023974 @default.
• W3134973524 date "2021-05-20" @default.
• W3134973524 modified "2023-09-25" @default.
• W3134973524 title "Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence" @default.
• W3134973524 cites W1518500152 @default.
• W3134973524 cites W1694864989 @default.
• W3134973524 cites W1965983395 @default.
• W3134973524 cites W1976431364 @default.
• W3134973524 cites W1976461323 @default.
• W3134973524 cites W1984505168 @default.
• W3134973524 cites W1986548413 @default.
• W3134973524 cites W1988402105 @default.
• W3134973524 cites W1989230896 @default.
• W3134973524 cites W1997116028 @default.
• W3134973524 cites W2009618668 @default.
• W3134973524 cites W2018136890 @default.
• W3134973524 cites W2019707058 @default.
• W3134973524 cites W2022787364 @default.
• W3134973524 cites W2025856071 @default.
• W3134973524 cites W2034737905 @default.
• W3134973524 cites W2036700635 @default.
• W3134973524 cites W2043270340 @default.
• W3134973524 cites W2047610334 @default.
• W3134973524 cites W2048077192 @default.
• W3134973524 cites W2061782635 @default.
• W3134973524 cites W2063079876 @default.
• W3134973524 cites W2063482332 @default.
• W3134973524 cites W2068380871 @default.
• W3134973524 cites W2069885091 @default.
• W3134973524 cites W2072486526 @default.
• W3134973524 cites W2074863161 @default.
• W3134973524 cites W2074914062 @default.
• W3134973524 cites W2082908110 @default.
• W3134973524 cites W2090416615 @default.
• W3134973524 cites W2092504356 @default.
• W3134973524 cites W2095216835 @default.
• W3134973524 cites W2098923148 @default.
• W3134973524 cites W2099191115 @default.
• W3134973524 cites W2104255009 @default.
• W3134973524 cites W2106131368 @default.
• W3134973524 cites W2107949967 @default.
• W3134973524 cites W2108018100 @default.
• W3134973524 cites W2126930838 @default.
• W3134973524 cites W2130252111 @default.
• W3134973524 cites W2144248454 @default.
• W3134973524 cites W2160712198 @default.
• W3134973524 cites W2164105256 @default.
• W3134973524 cites W2322829433 @default.
• W3134973524 cites W2406180991 @default.
• W3134973524 cites W2411519439 @default.
• W3134973524 cites W2419119392 @default.
• W3134973524 cites W2427527050 @default.
• W3134973524 cites W2616114255 @default.
• W3134973524 cites W2621248530 @default.
• W3134973524 cites W2664858983 @default.
• W3134973524 cites W2788086150 @default.
• W3134973524 cites W2887678989 @default.
• W3134973524 cites W2893335423 @default.
• W3134973524 cites W2948080067 @default.
• W3134973524 cites W2954097581 @default.
• W3134973524 cites W2984000923 @default.
• W3134973524 cites W2994662660 @default.
• W3134973524 cites W3022903699 @default.
• W3134973524 doi "https://doi.org/10.1080/03007995.2021.1895095" @default.
• W3134973524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33651656" @default.
• W3134973524 hasPublicationYear "2021" @default.
• W3134973524 type Work @default.
• W3134973524 sameAs 3134973524 @default.
• W3134973524 citedByCount "3" @default.
• W3134973524 countsByYear W31349735242021 @default.
• W3134973524 countsByYear W31349735242022 @default.
• W3134973524 countsByYear W31349735242023 @default.
• W3134973524 crossrefType "journal-article" @default.
• W3134973524 hasAuthorship W3134973524A5011519841 @default.
• W3134973524 hasAuthorship W3134973524A5045023974 @default.
• W3134973524 hasBestOaLocation W31349735241 @default.
• W3134973524 hasConcept C118552586 @default.
• W3134973524 hasConcept C126322002 @default.
• W3134973524 hasConcept C142724271 @default.
• W3134973524 hasConcept C156957248 @default.
• W3134973524 hasConcept C181199279 @default.
• W3134973524 hasConcept C185592680 @default.
• W3134973524 hasConcept C204787440 @default.
• W3134973524 hasConcept C27081682 @default.
• W3134973524 hasConcept C2776024655 @default.
• W3134973524 hasConcept C2776412080 @default.
• W3134973524 hasConcept C2777118369 @default.
• W3134973524 hasConcept C2780494398 @default.
• W3134973524 hasConcept C55493867 @default.
• W3134973524 hasConcept C71924100 @default.
• W3134973524 hasConcept C95190672 @default.
• W3134973524 hasConcept C98274493 @default.
• W3134973524 hasConceptScore W3134973524C118552586 @default.
• W3134973524 hasConceptScore W3134973524C126322002 @default.
• W3134973524 hasConceptScore W3134973524C142724271 @default.

• next